RogersSL, FriedhoffLT. Donepezil study group. The efficacy and safety of donezepil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial.Dementia1996; 7: 293–303.
2.
RogersSL, DoodyR, MohsR.E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): results of a 30 week phase III trial.Neurology1996; 46(suppl): A217.
3.
KellyC, HarveyRJ, CaytonH.Drug treatments for Alzheimer's disease raise clinical and ethical problems.BMJ1997; 314: 693–4.
4.
Royal College of Psychiatrists, Section for Psychiatry of Old Age.Interim Statement on Anti-dementia drugs—Implications, Concerns and Policy Proposals.London: Royal College of Psychiatrists, 1997.
5.
WilkinsonDG. Comment on Alzheimer's disease: A survey of clinical directors.Geriatr Med1997; April: 60–1.
6.
GrayS.Advertisement for donepezil (Aricept) in the BMJ [Letter].BMJ1997; 314: 1555.
7.
WagnerN.Advertisement for donepezil (Aricept) in the BMJ [Letter].BMJ1997; 314: 1555–6.
8.
McKeithI.Alzheimer's disease—a suitable case for treatment?Prog Neurol Psychiatry1997; 1: 7–8.
9.
SmithK, ShahAK, WrightK, LewisG.The prevalence and cost of psychiatric disorders and learning disabilities.Br J Psychiatry1995; 166: 9–18.
10.
GrayA, FennP.Alzheimer's disease: the burden of illness in England.Health Trends1993; 25: 31–7.
11.
KnopmanD, SchneiderL, DavisK.Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Tacrine study group.Neurology1996; 47: 166–7.
12.
LubeckDP, MazonsonPD, BoweT.Potential effects of tacrine on expenditure for Alzheimer's disease.Med Interface1994; 7: 130–8.
